|
Mountain View, Calif. November 29, 2001 SurroMed, Inc. today
announced the appointment of Howard Schulman, Ph.D., to the position
of vice president of research and development. Dr Schulman is
a founding co-director of the Stanford Brain Research Center and
former chairman of the Department of Neurobiology, Stanford University
School of Medicine. He will direct SurroMed's biomarker discovery
initiative focused on enabling the precise diagnosis and effective
treatment of disease.
Dr. Schulman, 52, has served as a professor at the Stanford University
School of Medicine since 1991, in the Department of Pharmacology
and subsequently also in the Department of Neurobiology. He has
been a major contributor to progress in the field of molecular
pharmacology research for more than 20 years with over 100 peer
reviewed articles. Dr. Schulman discovered one of the key protein
kinases responsible for transmitting information from calcium-linked
hormones, neurotransmitters, and cytokines in heart and brain.
The kinase is currently under investigation by several pharmaceutical
companies in the CNS and cardiovascular arenas. Dr. Schulman has
spent the last year at SurroMed as a visiting scientist while
on leave from Stanford Medical School.
"Howard has already made a substantial contribution to SurroMed's
biomarker discovery efforts during his sabbatical year from Stanford,
and we are thrilled that he has decided to join us," said
Gordon Ringold, Ph.D., SurroMed's co-founder, chairman and chief
executive officer. "His expertise and depth of knowledge
in neurobiology and molecular pharmacology will advance our efforts
in biomarker discovery and advance our diagnostic and therapeutic
businesses."
Dr. Schulman received his Ph.D. in biological chemistry at Harvard
University, studying lipid and carbohydrate metabolism. Subsequently
he undertook postdoctoral research focused on pharmacology and
signal transduction in the nervous system at Yale University School
of Medicine under the supervision of Nobel Laureate Paul Greengard,
Ph.D. He joined the Stanford University School of Medicine as
an assistant professor and became chairman of the Department of
Neurobiology in 1995. He is a member of the editorial board of
the Journal of Biological Chemistry, Journal of Neurochemistry,
Molecular Neurobiology and Genes to Cells. Dr. Schulman is married
with two children.
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed uses its
integrated phenotyping and biological marker discovery platform
to better understand the root causes of disease and the factors
underlying patient-to-patient variations in disease presentation,
progression and response to therapy. Discoveries arising from
its research will enable improved, cost-efficient discovery and
development of therapeutic and diagnostic products. SurroMed's
phenotyping and biological marker discovery platform incorporates
advanced proprietary technologies for profiling and analysis of
hundreds of immune cell populations, proteins and low-molecular-weight
organic molecules (such as sugars, peptides or lipids) in small
volumes of blood and/or other biological samples, while maintaining
complete patient confidentiality. By capturing and analyzing enormous
amounts of clinical and biological information in a massively
parallel fashion to identify useful biological markers, SurroMed
plans to enable the precise diagnosis and effective treatment
of disease.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Noonan/Russo Communications, Inc.
Ian McConnell, Ph.D
Senior Account Executive
(415) 677-4455 ext. 233
email: [email protected]
|
